Erratum: Peripheral Measurable Residual Disease Activity Assessment by MALDI-TOF Mass Spectrometry in Patients With Newly Diagnosed Multiple Myeloma in the Phase III GMMG-HD7 Trial The article by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results